Amylin Biology
Amylin (islet amyloid polypeptide, IAPP) is a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells. It has been investigated in preclinical research for its roles in gastric emptying regulation, appetite suppression via brainstem signaling, and glucagon secretion modulation. Native amylin is rapidly degraded and prone to aggregation, making synthetic analogs valuable research tools.
Cagrilintide: A Long-Acting Amylin Analog
Cagrilintide is an acylated amylin analog designed for extended duration of action. Structural modifications reduce aggregation propensity while a fatty acid modification promotes albumin binding for extended half-life. In preclinical studies, cagrilintide has been investigated for effects on food intake, body composition, and metabolic parameters in animal models.
Combination Research with GLP-1 Agonists
A particularly active area of preclinical investigation involves combining cagrilintide with GLP-1 receptor agonists such as semaglutide. The rationale is that amylin and GLP-1 act on distinct but complementary appetite-regulating pathways in the central nervous system, potentially producing additive or synergistic effects in research models.
Implications for Metabolic Research
Cagrilintide research contributes to the broader understanding of the role of pancreatic peptide hormones in metabolic regulation. For researchers studying multi-target approaches to metabolic pathway modulation, the combination of amylin and incretin agonism offers a valuable experimental framework. Explore ROEHN's metabolic research peptide catalog, including Semaglutide and Tirzepatide.
Research Disclaimer
This article is for educational and informational purposes only. All compounds discussed are intended strictly for in-vitro and preclinical research use. They are not intended for human consumption. Always consult published scientific literature and institutional review protocols before initiating any research program.